Arena Pharmaceuticals completes full enrollment in Etrasimod Phase 2 study
Arena Pharmaceuticals announced that it has completed full enrollment in the etrasimod Phase 2 study in ulcerative colitis. Etrasimod is an investigational-stage, oral, next-generation, sphingosine-1-phosphate receptor modulator with improved pharmacology and pharmacokinetics intended for the treatment of autoimmune diseases. The study enrolled 157 patients at sites globally. The study is a 12-week, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging trial evaluating safety and tolerability. Efficacy endpoints include improvement in the Mayo clinical score, response, remission and mucosal healing versus placebo, and dose response. The study enrolled patients with moderate to severe UC.